Primary treatment patterns and survival of cervical cancer in Sweden : A population-based Swedish Gynecologic Cancer Group Study
(2019) In Gynecologic Oncology 155(2). p.229-236- Abstract
Objective: Survival in cervical cancer has improved little over the last decades. We aimed to elucidate primary treatment patterns and survival. Methods: Population-based study of patients included in the Swedish Quality Registry for Gynecologic Cancer diagnosed 2011–2015. Main outcome was 5-year relative survival (RS). Age-standardised RS (AS-RS) was estimated for the total cohort and for the pooled study population of squamous, adenosquamous-, adenocarcinoma. Results: Median follow-up time was 4.6 years. The study population consisted of 2141 patients; 97% of the 2212 patients in the total cohort and the 5-year AS-RS was 71% and 70%, respectively. RS stage IB1: surgery alone 95% vs. 72% for definitive chemoradiotherapy (CT-RT) (p <... (More)
Objective: Survival in cervical cancer has improved little over the last decades. We aimed to elucidate primary treatment patterns and survival. Methods: Population-based study of patients included in the Swedish Quality Registry for Gynecologic Cancer diagnosed 2011–2015. Main outcome was 5-year relative survival (RS). Age-standardised RS (AS-RS) was estimated for the total cohort and for the pooled study population of squamous, adenosquamous-, adenocarcinoma. Results: Median follow-up time was 4.6 years. The study population consisted of 2141 patients; 97% of the 2212 patients in the total cohort and the 5-year AS-RS was 71% and 70%, respectively. RS stage IB1: surgery alone 95% vs. 72% for definitive chemoradiotherapy (CT-RT) (p < 0.001). In stage IIA1 74% had CT-RT, and 47% of operated patients received adjuvant (CT)-RT. RS stage IB2: surgically treated 81% (69% received adjuvant (CT)-RT) vs. 76% for (CT)-RT (p = 0.73). RS stage IIB: 77% for CT-RT + brachytherapy (BT), 37% for RT + BT (p = 0.045) and 27% for RT-BT (p < 0.001). Stages III-IVA; <40% received CT-RT + BT, RS 45% vs. 18% for RT-BT (RR 4.1, p < 0.001). RS stage IVB 7%. Conclusion: Primary treatment of cervical cancer in Sweden adhered to evidence-based standard of care. Areas of improvement include optimising treatment for stages III-IVA, and avoiding combining surgery and radiotherapy.
(Less)
- author
- organization
- publishing date
- 2019-11
- type
- Contribution to journal
- publication status
- published
- subject
- keywords
- Cervical cancer, Radiotherapy, Surgery, Survival, Treatment
- in
- Gynecologic Oncology
- volume
- 155
- issue
- 2
- pages
- 8 pages
- publisher
- Academic Press
- external identifiers
-
- pmid:31477283
- scopus:85071486769
- ISSN
- 0090-8258
- DOI
- 10.1016/j.ygyno.2019.08.022
- language
- English
- LU publication?
- yes
- id
- b821bca2-5168-400c-b479-bb42d58248ab
- date added to LUP
- 2019-09-19 12:27:47
- date last changed
- 2024-09-19 10:09:52
@article{b821bca2-5168-400c-b479-bb42d58248ab, abstract = {{<p>Objective: Survival in cervical cancer has improved little over the last decades. We aimed to elucidate primary treatment patterns and survival. Methods: Population-based study of patients included in the Swedish Quality Registry for Gynecologic Cancer diagnosed 2011–2015. Main outcome was 5-year relative survival (RS). Age-standardised RS (AS-RS) was estimated for the total cohort and for the pooled study population of squamous, adenosquamous-, adenocarcinoma. Results: Median follow-up time was 4.6 years. The study population consisted of 2141 patients; 97% of the 2212 patients in the total cohort and the 5-year AS-RS was 71% and 70%, respectively. RS stage IB1: surgery alone 95% vs. 72% for definitive chemoradiotherapy (CT-RT) (p < 0.001). In stage IIA1 74% had CT-RT, and 47% of operated patients received adjuvant (CT)-RT. RS stage IB2: surgically treated 81% (69% received adjuvant (CT)-RT) vs. 76% for (CT)-RT (p = 0.73). RS stage IIB: 77% for CT-RT + brachytherapy (BT), 37% for RT + BT (p = 0.045) and 27% for RT-BT (p < 0.001). Stages III-IVA; <40% received CT-RT + BT, RS 45% vs. 18% for RT-BT (RR 4.1, p < 0.001). RS stage IVB 7%. Conclusion: Primary treatment of cervical cancer in Sweden adhered to evidence-based standard of care. Areas of improvement include optimising treatment for stages III-IVA, and avoiding combining surgery and radiotherapy.</p>}}, author = {{Bjurberg, Maria and Holmberg, Erik and Borgfeldt, Christer and Flöter-Rådestad, Angelique and Dahm-Kähler, Pernilla and Hjerpe, Elisabet and Högberg, Thomas and Kjølhede, Preben and Marcickiewicz, Janusz and Rosenberg, Per and Stålberg, Karin and Tholander, Bengt and Hellman, Kristina and Åvall-Lundqvist, Elisabeth}}, issn = {{0090-8258}}, keywords = {{Cervical cancer; Radiotherapy; Surgery; Survival; Treatment}}, language = {{eng}}, number = {{2}}, pages = {{229--236}}, publisher = {{Academic Press}}, series = {{Gynecologic Oncology}}, title = {{Primary treatment patterns and survival of cervical cancer in Sweden : A population-based Swedish Gynecologic Cancer Group Study}}, url = {{http://dx.doi.org/10.1016/j.ygyno.2019.08.022}}, doi = {{10.1016/j.ygyno.2019.08.022}}, volume = {{155}}, year = {{2019}}, }